Additional advantages of pre‐operative statin use in patients undergoing non‐cardiac vascular surgery

Paraskevas, Kosmas I.; Perrea, Despina; Mikhailidis, D. P.

doi:10.1111/j.1365-2044.2008.05548.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Benefit Assessment1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both are mentioned in the SIGN 26 besides their well known lipid lowering effects and benefit on cardiovascular and cerebrovascular morbidity and mortality. They also might play a beneficial role in pre-operative use in vascular surgery, in renal protection which further promotes them for standard use in the vulnerable PAD patients [31][32][33][34][35] . Side effects include myalgia with risk of rhabdomyolysis, mainly in combination with other drugs, increased liver enzymes, central effects and polyneuritis 36 .…”

Section: Benefit Assessmentmentioning

confidence: 99%

Silence of the Limbs: Pharmacological Symptomatic Treatment of Intermittent Claudication

Backer

Stichele²,

Buyzere³

et al. 2010

CVP

View full text Add to dashboard Cite

Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules. Although spanning several decades, several studies underlying these claims were not properly designed, underpowered or showed clinically doubtful outcomes. The evidence for these "vasoactive" drugs has always been received with scepticism, creating the need for systematic reviews and metaanalyses. This brief review discusses the benefit-risk assessment of vasoactive drugs, by applying a systematic review to evaluate randomized, placebo-controlled trials.

show abstract